New Approach to Assessment of Cardioselectivity of Beta-blocking Drugs

Kumana, C. R.; Marlin, G. E.; Kaye, C. M.; Smith, D. M.
November 1974
British Medical Journal;11/23/1974, Vol. 4 Issue 5942, p444
Academic Journal
No abstract available.


Related Articles

  • HYPERTENSION: β-BLOCKER PHARMACOKINETICS.  // Monthly Prescribing Reference;Sep2013, Vol. 29 Issue 9, p31 

    A chart depicting Beta-blocker pharmacokinetics comparison for hypertension, including the generic drugs, betaxolol, atenolol, and acebutolol along with their composition, Cardioselectivity, and target site is presented.

  • Drug options for angina little changed. Mann, Stewart // New Zealand Doctor;3/11/2009, p22 

    The article focuses on the drug options for angina which include nitrates, beta-blockers and calcium channel blockers. Nitrates are said to have been known to be valuable for the relief of angina symptoms but patients given nitrates are cautioned about possible headache and hypotension....

  • STUDIJE ISHODA LEÄŒENJA BETA BLOKATORIMA U SEKUNDARNOJ PREVENCIJI ISHEMIJSKE BOLESTI SRCA. Radović, Vesna V. // Medicinski Pregled / Medical Review;2009, Vol. 62 Issue 9/10, p450 

    Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are...

  • Leczenie beta-blokerami w astmie. Kowal, Krzysztof // Alergia Astma Immunologia;2011, Vol. 16 Issue 4, p172 

    Beta-blockers have been for years considered contraindicated in asthmatic patients. However, the beneficial effects in cardiovascular diseases, including reduction of mortality due to heart problems, make beta-blockers highly desired in patients suffering from ischemic heart disease or...

  • Changing beta-blockers in heart failure: when is a class not a class? Aronson, Jeffrey K. // British Journal of General Practice;Jun2008, Vol. 58 Issue 551, p387 

    The author focuses on drug classes. He notes that a drug class relies on its main pharmacological target of action yet not all classes are defined according to their target. He adds that drugs within a class that has a single main target may also deliver actions on other subsidiary targets. He...

  • metoprolol. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p505 

    An encyclopedia entry for "metoprolol" is presented. It is a cardioselective beta-blocker drug that acts mainly on nerve endings in the heart and blood vessels. The drug is used to prevent the heart from beating too fast, in angina pectoris and for hypertension. Metoprolol is also administered...

  • Considerations in treating acute coronary syndromes with possible coexisting asthma. Haines, Erica // British Journal of Cardiac Nursing;Feb2011, Vol. 6 Issue 2, p58 

    When a patient presents with symptoms of an acute coronary syndrome (ACS) routine administration of antiplatelet and betablocking therapy is recommended according to the NICE guidance (Cooper 2010). However certain comorbid conditions that may point to underlying asthma should be considered and...

  • Possible metabolic side effects of beta-adrenergic blocking drugs. Hielgeland, A.; Hjermann, I.; Leren, P.; Holme, I. // British Medical Journal;4/1/1978, Vol. 1 Issue 6116, p828 

    Recent reports have described the increase in serum lipid concentrations that occur during thiazide treatment.[1 2] The effects of -adrenergic drugs on triglycerides and cholesterol are more uncertain, but an increase in triglyceride concentrations has been shown during treatment with a...

  • Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Wilcox, R.G. // British Medical Journal;8/5/1978, Vol. 2 Issue 6134, p383 

    Examines the effectiveness of beta-blockers and thiazide diuretic in the treatment of essential hypertension. Assessment of incidence of drug side effects; Evaluation of standing blood pressure after treatment; Major disadvantage of the use of beta-blockers.

  • Review: Cardioselective β-blockers do not produce adverse respiratory effects in COPD: COMMENTARY. Lacasse, Yves // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p66 

    The article presents comments of the author on a study which found that cardioselective β-blockers do not produce adverse respiratory effects in COPD. The well-conducted meta-analysis by researchers of the study vividly illustrates one of the assumptions of the new paradigm of evidence-based...


Read the Article

Other Topics